Physician profile
Patrick H Peters
NPI 1578505731
$11,541.09
in general payments reported to CMS, 2019-2025
34 companies · $1,789 in 2025
The $1,789 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,349 · 2020: $768 · 2021: $1,241 · 2022: $2,223 · 2023: $961 · 2024: $1,210 · 2025: $1,789.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,961.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,960.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,546.09 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $1,015.06 | 2021-2025 | Evenity, Repatha, Otezla |
| Novo Nordisk INC | $871.58 | 2019-2022 | |
| Lilly USA, LLC | $718.47 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Esperion Therapeutics, INC. | $694.42 | 2021-2024 | Nexlizet, Nexletol |
| Si-Bone, INC. | $585.94 | 2019-2025 | |
| Amarin Pharma, INC. | $458.52 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $425.55 | 2021-2023 | Nuzyra |
| Medtronic, INC. | $383.70 | 2024-2025 | Signia, Affera Mapping System, Cobalt Dr Mri Surescan |
| Bayer Healthcare Pharmaceuticals INC. | $372.01 | 2021-2022 | |
| Abbvie INC. | $344.97 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $324.82 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $312.14 | 2019-2023 | Xarelto |
| Regeneron Pharmaceuticals, INC. | $284.13 | 2019-2022 | |
| Abbott Laboratories | $268.15 | 2021-2025 | Amplatzer Amulet |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $246.69 | 2023-2024 | Nuedexta |
| Boston Scientific Corporation | $188.90 | 2019-2020 | |
| Atricure, INC. | $155.90 | 2025 | Epi-Sense Guided Coagulation System With Visitrax, Atriclip Laa Exclusion System |
| Averitas Pharma INC. | $147.49 | 2025 | Qutenza |
| Idorsia Pharmaceuticals US INC | $131.10 | 2022-2023 | Quviviq |
| Biotronik INC. | $126.12 | 2025 | Rivacor 7 Dr-T, Biomonitor, Amvia Edge |
| Biohaven Pharmaceutical Holding Company LTD. | $124.64 | 2022 | |
| Glaxosmithkline, LLC. | $114.26 | 2019 | |
| Eisai INC. | $113.65 | 2021 | |
| Biosense Webster, INC. | $109.51 | 2019 | |
| Exactech, INC. | $106.59 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $100.00 | 2019 | |
| Urovant Sciences INC | $98.68 | 2022 | |
| Corcept Therapeutics | $81.91 | 2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $30.26 | 2019 | |
| Alnylam Pharmaceuticals INC. | $22.89 | 2025 | Onpattro |
| Tolmar, INC. | $21.81 | 2023 | |
| Novartis Pharmaceuticals Corporation | $15.14 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Peters listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.